Patent US4582797A successfully refreshed from Google Patents.
US4582797A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoclonal antibodies specific for human hematopoietic cell surface glycoproteins
Assignee: Salk Institute for Biological Studies
•
Filing: 1983-02-28
•
Granted: 1986-04-15
•
Expires: 2003-02-28
Abstract
Abstract Monoclonal antibodies are produced for a family of glycoproteins which are selectively expressed on the surface of nucleated human hematopoietic cells but which are absent from other normal human cells. Mice are inoculated with human hematopoietic cells or fragments thereof, and spleen cells obtained from the mice are fused with murine myeloma cells to produce hybridomas. The hybridomas are cultured as clones, and antibodies obtained from the individual clones are tested for their specificity for surface glycoproteins of nucleated human hematopoietic cells. Antibodies can be obtained from the culture growth medium or from ascitic fluid of mice bearing the hybridoma tumor and can be used to distinguish lymphomas from carcinomas.
Inventors
- 👤 Ian S. Trowbridge
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 08:21
CPC Classifications
C; C07; C07K; C07K16/00; C07K16/18; C07K16/28; C07K16/289
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
80 words
A mouse monoclonal antibody produced by a hybridoma formed by fusion of cells from a mouse myeloma line and either spleen cells or lymph node cells from a mouse previously immunized with human hematopoietic cells, which antibody reacts with specific hematopoietic cell surface glycoproteins that react with monoclonal antibody produced by cell line ATCC CRL 8036, which glycoproteins are present in essentially all human nucleated hematopoietic cells, but said monoclonal antibody does not react with other normal human tissue cells.
Claim 2
Dependent Claim
80 words
A mouse monoclonal antibody produced by a hybridoma formed by fusion of cells from a mouse myeloma line and either spleen cells or lymph node cells from a mouse previously immunized with human hematopoietic cells, which antibody reacts with specific hematopoietic cell surface glycoproteins that react with monoclonal antibody produced by cell line ATCC CRL 8036, which glycoproteins are present in essentially all human nucleated hematopoietic cells, but said monoclonal antibody does not react with other normal human tissue cells.
Claim 3
Dependent Claim
33 words
The monoclonal antibody of claim 1 which is produced from a hybridoma formed by the fusion of S194/5.XX0.BU.1 myeloma cells and cells from a mouse previously immunized with CCRF-CEM human T leukemic cells.
Claim 4
Independent Claim
46 words
The method of preparing monoclonal antibodies which react with essentially all nucleated hematopoietic cells but do not react with other normal human tissue cells, which method comprises either culturing in vitro or injecting into a histocompatible animal the hybridoma ATCC CRL 8036 and recovering the antibodies.
Claim 5
Independent Claim
46 words
The method of preparing monoclonal antibodies which react with essentially all nucleated hematopoietic cells but do not react with other normal human tissue cells, which method comprises either culturing in vitro or injecting into a histocompatible animal the hybridoma ATCC CRL 8036 and recovering the antibodies.
Claim 6
Dependent Claim
24 words
A method in accordance with claim 3 wherein said hybridoma is injected into athymic nude mice and recovering the antibodies from ascitic fluid therefrom.
Claim 7
Dependent Claim
186 words
A monoclonal antibody which reacts with specific hematopoietic cell surface glycoproteins that react with monoclonal antibody produced by cell line ATCC CRL 8036, which glycoproteins are present in essentially all human nucleated hematopoietic cells, but said antibody does not react with other normal human tissue cells, the monoclonal antibody prepared by the method comprising the steps of: (a) immunizing mice with human hematopoietic cell; (b) removing the spleens from said mice and making a suspension of the spleen cells; (c) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (d) diluting and separately culturing the fused cells in a medium which will only support growth of fused myeloma cells; (e) examining the medium from each of the separate cultures containing a hybridoma for the presence of antibodies which react with human hematopoietic cells; (f) selecting and cloning a hybridoma producing a monoclonal antibody which reacts with cell surface glycoproteins particular to all human nucleated hematopoietic cells, and specifically with said cell surface glycoproteins, but not with cell surface glycoproteins from other normal tissue cells; and (g) recovering said monoclonal antibody.
Claim 8
Dependent Claim
186 words
A monoclonal antibody which reacts with specific hematopoietic cell surface glycoproteins that react with monoclonal antibody produced by cell line ATCC CRL 8036, which glycoproteins are present in essentially all human nucleated hematopoietic cells, but said antibody does not react with other normal human tissue cells, the monoclonal antibody prepared by the method comprising the steps of: (a) immunizing mice with human hematopoietic cell; (b) removing the spleens from said mice and making a suspension of the spleen cells; (c) fusing said spleen cells with mouse myeloma cells in the presence of a fusion promoter; (d) diluting and separately culturing the fused cells in a medium which will only support growth of fused myeloma cells; (e) examining the medium from each of the separate cultures containing a hybridoma for the presence of antibodies which react with human hematopoietic cells; (f) selecting and cloning a hybridoma producing a monoclonal antibody which reacts with cell surface glycoproteins particular to all human nucleated hematopoietic cells, and specifically with said cell surface glycoproteins, but not with cell surface glycoproteins from other normal tissue cells; and (g) recovering said monoclonal antibody.
Claim 9
Dependent Claim
29 words
The monoclonal antibody of claim 5 which is prepared by injecting said hybridoma clones intraperitoneally into a histocompatible animal and recovering said antibody from ascitic fluid of the animal.
Claim 10
Dependent Claim
22 words
The monoclonal antibody of claim 5 prepared by the method wherein BALB/c mice are immunized with CCRF-CEM normal human T leukemic cells.
Claim 11
Dependent Claim
21 words
The monoclonal antibody of claim 7 prepared by the method wherein said spleen cells are fused with SI94/5.XX0.BU.1 mouse myeloma cells.
Claim 12
Dependent Claim
15 words
The monoclonal antibody according to claim 5 produced by the cell line ATCC CRL 8036.
References Cited (Backward Citations)
US4196265A
Cited
US4172124A
Cited
US4363799A
Cited
US4361549A
Cited
US4271145A
Cited
US4364933A
Cited
US4364935A
Cited
US4364937A
Cited
US4364936A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-04-14 | 1989-10-14 | 1990-04-15 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-04-14 | 1993-10-14 | 1994-04-15 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-04-14 | 1997-10-14 | 1998-04-15 | $7700.00 | Window Closed / Lapsed |